KR20120050473A - 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 - Google Patents

탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 Download PDF

Info

Publication number
KR20120050473A
KR20120050473A KR1020127006244A KR20127006244A KR20120050473A KR 20120050473 A KR20120050473 A KR 20120050473A KR 1020127006244 A KR1020127006244 A KR 1020127006244A KR 20127006244 A KR20127006244 A KR 20127006244A KR 20120050473 A KR20120050473 A KR 20120050473A
Authority
KR
South Korea
Prior art keywords
neuro
aminopyridine
cognitive
patient
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127006244A
Other languages
English (en)
Korean (ko)
Inventor
토마스 씨 웨셀
앤드류 블라이트
Original Assignee
아코르다 쎄라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아코르다 쎄라퓨틱스 인코포레이티드 filed Critical 아코르다 쎄라퓨틱스 인코포레이티드
Publication of KR20120050473A publication Critical patent/KR20120050473A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020127006244A 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 Ceased KR20120050473A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US23306909P 2009-08-11 2009-08-11
US23307709P 2009-08-11 2009-08-11
US61/233,077 2009-08-11
US61/233,069 2009-08-11
US23987709P 2009-09-04 2009-09-04
US61/239,877 2009-09-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177032919A Division KR20170128633A (ko) 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도

Publications (1)

Publication Number Publication Date
KR20120050473A true KR20120050473A (ko) 2012-05-18

Family

ID=43586462

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127006244A Ceased KR20120050473A (ko) 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
KR1020177032919A Ceased KR20170128633A (ko) 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177032919A Ceased KR20170128633A (ko) 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도

Country Status (17)

Country Link
US (8) US20130053420A1 (enExample)
EP (1) EP2464229B1 (enExample)
JP (2) JP6137833B2 (enExample)
KR (2) KR20120050473A (enExample)
CN (1) CN102143687B (enExample)
AR (1) AR077858A1 (enExample)
AU (1) AU2010282509B2 (enExample)
BR (1) BRPI1003991A2 (enExample)
CA (1) CA2770698C (enExample)
ES (1) ES2563751T3 (enExample)
JO (1) JO3348B1 (enExample)
MX (1) MX2012001814A (enExample)
RU (1) RU2563821C2 (enExample)
TW (2) TWI549678B (enExample)
UY (1) UY32837A (enExample)
WO (1) WO2011019845A1 (enExample)
ZA (1) ZA201201001B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20130184316A1 (en) * 2010-07-15 2013-07-18 Andrew Hornstein Methods for diagnosing and treating concussive disorders
JP2014503596A (ja) * 2011-01-28 2014-02-13 アコーダ セラピューティクス，インコーポレーテッド 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
US10793893B2 (en) 2011-06-30 2020-10-06 Serb Sa Methods of administering 3,4-diaminopyridine
WO2014138298A1 (en) * 2013-03-05 2014-09-12 University Of Chicago Treatment of demyelinating disorders
WO2014172266A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
DE102014221687B4 (de) * 2014-10-24 2019-07-04 Danfoss Silicon Power Gmbh Leistungshalbleitermodul mit kurzschluss-ausfallmodus
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
WO2002072025A2 (en) * 2001-03-14 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Improving postsynaptic response by a combination of 4-minopyridine and agonist
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
JP6137833B2 (ja) 2017-05-31
US20200113882A1 (en) 2020-04-16
US20190015399A1 (en) 2019-01-17
CN102143687A (zh) 2011-08-03
AU2010282509A1 (en) 2012-03-01
AR077858A1 (es) 2011-09-28
JP2013501805A (ja) 2013-01-17
US20160213661A1 (en) 2016-07-28
US20190247379A1 (en) 2019-08-15
ZA201201001B (en) 2014-10-29
TW201110967A (en) 2011-04-01
CN102143687B (zh) 2015-11-25
EP2464229A4 (en) 2013-02-13
UY32837A (es) 2011-03-31
MX2012001814A (es) 2012-06-01
ES2563751T3 (es) 2016-03-16
AU2010282509B2 (en) 2015-07-30
HK1173911A1 (zh) 2013-05-31
TWI549678B (zh) 2016-09-21
CA2770698A1 (en) 2011-02-17
JO3348B1 (ar) 2019-03-13
WO2011019845A1 (en) 2011-02-17
EP2464229B1 (en) 2015-11-25
RU2012108656A (ru) 2013-09-20
EP2464229A1 (en) 2012-06-20
US20170056385A1 (en) 2017-03-02
JP2016074728A (ja) 2016-05-12
BRPI1003991A2 (pt) 2015-09-15
TW201613585A (en) 2016-04-16
KR20170128633A (ko) 2017-11-22
CA2770698C (en) 2018-01-30
US20170281608A1 (en) 2017-10-05
RU2563821C2 (ru) 2015-09-20
US20180147193A1 (en) 2018-05-31
US20130053420A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
KR20140054129A (ko) 라퀴니모드와 인터페론-베타의 병용에 의한 다발성 경화증의 치료
KR20170122777A (ko) 트라디피턴트에 의한 치료 방법
US20200113883A1 (en) Durable treatment with 4-aminopyridine in patients with demyelination
CN115776894A (zh) T型钙通道调节剂的使用方法
TW202131910A (zh) 使用mtorc1調節劑的治療方法
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
JP2015522077A (ja) ラキニモドおよびファムプリジンの組合せによる多発性硬化症の治療
EP2727595B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
HK1173911B (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with multiple sclerosis
OA16802A (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120309

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150810

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161017

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170417

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161017

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170417

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170217

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150810

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170816

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170717

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170417

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170217

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20161017

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150810

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171114

PJ0201 Trial against decision of rejection

Patent event date: 20171114

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170816

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20170417

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190828

Appeal identifier: 2017101005488

Request date: 20171114

J301 Trial decision

Free format text: TRIAL NUMBER: 2017101005488; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20171114

Effective date: 20190828

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20190828

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20171114

Decision date: 20190828

Appeal identifier: 2017101005488